Using fluorescent indicators to measure oxidative stress in Alzheimer's disease
Official title: Fluorescent Redox Indicators to Image Oxidative Stress in Alzheimer's Disease
Funded at University of Virginia · NIH-11212190 · Data updated 2026-11-12
This study is working on new tools to help scientists see how oxidative stress affects brain cells in mice with Alzheimer's disease, which could lead to better understanding and treatments for the condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Virginia NIH-funded |
| Lab location | 1 site (Charlottesville, United States) |
| Project start | May 1, 2022 |
| Project end | April 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $514,103 |
| NIH project number | 4R01AG077773-02 |
| Project ID | NIH-11212190 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation or benefit from this research are individuals at risk for or diagnosed with Alzheimer's disease, particularly those with age-related neurodegenerative conditions.
✕Less likely to help
Patients with non-neurodegenerative conditions or those not affected by age-related cognitive decline may not receive any benefit from this research.
What this research studies
This research focuses on developing genetically encoded fluorescent redox indicators (GERIs) to evaluate oxidative stress in mouse models of Alzheimer's disease (AD). By optimizing these indicators, the researchers aim to create tools that can easily measure oxidative stress levels during the progression of AD and in response to treatments. The study is led by a team with expertise in fluorescence imaging and metabolic drivers of cognitive disorders, which will enhance the understanding of oxidative stress's role in neuron death. This innovative approach could significantly advance research on AD and its underlying mechanisms.
Why it matters
Potential benefit: If successful, this research could lead to better diagnostic tools and therapeutic strategies for Alzheimer's disease by providing insights into oxidative stress.
How similar studies have gone: Previous research has shown success in using fluorescent indicators for imaging oxidative stress in various biological contexts, suggesting a promising avenue for this novel application in Alzheimer's disease.
Where this research is happening
-
University of Virginia
Charlottesville, United States Active
Researchers
- Principal investigator: Ai, Huiwang — University of Virginia
- Study coordinator: Ai, Huiwang
Related research
Other NIH-funded projects on the same topics.
-
Fluorescent sensors to visualize oxidative stress in Alzheimer's
They are creating tiny fluorescent sensors that light up where harmful oxidative stress happens in Alzheimer's models so researchers can see when and where damage occurs.
-
Effects of lipid droplets in brain cells on oxidative stress and Alzheimer's disease
This study is looking at how tiny fat droplets in brain cells might affect stress in the brain and lead to Alzheimer's disease, with the goal of finding early signs of risk so that we can help people sooner.
-
Investigating how oxidative stress affects blood vessels in Alzheimer's disease
This study is looking at how blood vessel health affects thinking and memory in Alzheimer's disease by using special imaging techniques on mice, hoping to find clues that could help us understand and spot brain damage related to the condition.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.